| Literature DB >> 30606201 |
Abstract
Acinetobacter baumannii is an important opportunistic pathogen due to its capabilities for developing mechanisms of resistance to a wide range of antimicrobial agents including carbapenems. This review described the risk factors, antimicrobial susceptibility and mechanisms of carbapenem resistance of A. baumannii from different geographical regions of Saudi Arabia. Several factors including complexity of intensive care unit (ICU) environments, increased numbers of patients with serious diseases, wide spread gastrointestinal colonization and extensive use of antimicrobial drugs led to a wide prevalence of A. baumannii infections in hospitals in Saudi Arabia. A. baumannii has been noted to be less susceptible to antimicrobials agents, including carbapenems, over time, resulting in the evolution of multidrug-resistant (MDR) strains. Dissemination of MDR A. baumannii is attributed to the extreme use of wide-spectrum antimicrobial drugs in hospitals, cross infection between inpatients, invasive ICU procedures, and hospitalized patients with diabetic and cancer those are under frequent invasive diagnostic and therapeutic interventions. Although an increasing prevalence of colistin and tigecycline resistance has been reported in many hospitals, combinations of these agents with carbapenems or other antibiotics remain the best therapeutic choice and reasonably safe to treat patients with MDR A. baumannii infections. The wide distribution of carbapenem resistant A. baumannii (CRAB) due to several mechanisms with diverse genetic determinants has been documented. Although OXA-23 β-lactamase and OXA-51 β-lactamase are the most common genes responsible for CRAB, other novel genes such as blaVIM, PER-1-like and GES-5 have been discovered in carbapenem resistant strains. The high rates of MDR A. baumannii in Saudi hospitals indicate that extensive investigation into the molecular basis of MDR and developing new therapies of CRAB is needed. Moreover, the development of a local antibiogram database coupled with a nationwide antimicrobial stewardship and infection prevention program might help to improve our knowledge of the resistance patterns of A. baumannii, and in developing a treatment protocol for decreasing the infection burden in Saudi Arabia.Entities:
Keywords: A. baumannii; Antimicrobial susceptibility; Carbapenem resistance mechanisms; Risk factors; Saudi Arabia
Mesh:
Substances:
Year: 2019 PMID: 30606201 PMCID: PMC6317247 DOI: 10.1186/s12941-018-0301-x
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Resistance rates of A. baumannii to different antimicrobial classes collected from hospitals of different geographical areas in Saudi Arabia
| Area | Region | Refs. | Year of survey | Penicillins | Cephalosporin’s | Carbapenems | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMC | PIP | PIP-TAZ | CFN | CFM | CAZ | CTX | AZO | IMP | MER | ||||
| Central | Qassim | [ | 2011 | – | – | 42 | – | 67 | 89 | – | – | 9 | – |
| Qassim | [ | 2014–2015 | 100 | 100 | – | – | – | 100 | – | – | – | – | |
| Riyadh | [ | 2006–2008 | – | – | – | – | 98.8 | – | 99.2 | – | 79.1 | 92.1 | |
| Riyadh | [ | 2006–2014 | – | – | – | – | 96.9 | 96.2 | 95.4 | – | 76.9 | 88.5 | |
| Riyadh | [ | 2009 | 96 | – | 93 | – | – | 88 | – | 83 | 89 | 91 | |
| Riyadh | [ | 2010 | – | – | – | – | 78 | 78 | – | 78 | 89 | 89 | |
| Riyadh | [ | 2011 | – | – | – | – | 100 | 100 | – | 100 | 63.6 | ||
| Riyadh | [ | 2006 | – | – | – | – | – | 75 | – | – | 36 | 19 | |
| 2012 | – | – | – | – | – | 83 | – | – | 91.7 | 89 | |||
| Riyadh | [ | 2013–2015 | – | – | – | – | 67.7 | 91.9 | – | – | 72.7 | 81.8 | |
| West | Jeddah | [ | 2012 | – | – | – | – | 27 | 25 | – | – | 66 | – |
| Jeddah | [ | 1999–2000 | 71 | 60 | – | – | – | 59 | 66 | 81 | 15 | – | |
| Makkah and Jeddah | [ | 2011 | – | 93.1 | – | – | 72.2 | 69.4 | 75 | 80.5 | 62.5 | – | |
| Madinah | [ | 2014 | 93.7 | 70.8 | – | 100 | – | 100 | – | 95.8 | – | – | |
| Madinah | [ | 6 month | 100 | – | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Makkah | [ | 2004–2005 | 87 | 73 | 8 | 92 | 45 | 79 | – | 90 | 14 | – | |
| Makkah | [ | 2005–2006 | 92.9 | – | – | 97.9 | – | 86.9 | 83.3 | 95.3 | 45.9 | 28 | |
| Makkah | [ | 2015 | – | – | – | – | 77 | 77 | 100 | – | 90 | 64 | |
| East | Dammam | [ | 2010–2012 | – | – | 33.3 | – | 73.8 | 85.1 | – | – | 32.6 | 33.3 |
| Dammam | [ | 2014 | – | – | – | 100 | – | – | – | – | – | ||
| Dammam and Dhahran | [ | 1998–2004 | – | – | – | 89 | – | 38 | – | – | 3 | – | |
| Dammam and Khobar | [ | 2015 | – | – | – | – | 67.7 | 71 | 87 | – | – | – | |
| Dammam | [ | 2014 | – | – | – | – | 100 | 100 | 100 | – | 100 | 100 | |
| South | Aseer | [ | 2011–2012 | – | – | – | – | – | 39 | – | – | 3 | – |
| Aseer | [ | 2013–2014 | – | 81.5 | – | – | 89.8 | – | – | – | 51.9 | 50 | |
| Aseer | [ | 2014–2015 | – | 97.1 | – | – | 96.6 | 92.7 | 97.8 | 92 | 95.5 | 100 | |
| Najran | [ | 2012–2013 | – | – | 32.4 | – | 45.6 | 91.2 | – | – | 7.4 | 1.5 | |
AK amikacin, AMC amoxicillin–clavulanic acid, AZO aztreonam, CAZ ceftazidime, CFM cefepime, CFN cefoxitin, CIP ciprofloxacin, CL colistin, CTX cefotaxime, CXM cefuroxime, GN gentamicin, IMI imipenem, MERO meropenem, PIP-TAZO piperacillin–tazobactam, SXT trimethoprim sulfamethoxazole, TIG tigecycline, TOB tobramicin
Types of carbapenems resistant genes carried by A. baumannii collected from various clinical specimens of patients at Saudi Arabia hospitals
| Region | Refs. | Year of sampling | Specimens | Sources of isolates | Setting | No. of carbapenems resistant isolates | Types of carbapenems genes (%) |
|---|---|---|---|---|---|---|---|
| Across KSA | [ | 2006–2007 | Sputum, urine, blood, ulcer | Inpatients and outpatients with DM | Different hospital wards | 20 | blaOXA-51 (45); blaOXA-131 (20) |
| Across KSA | [ | 2008–2011 | Blood, respiratory, urine, wound | Inpatients | ICUs | 196 | A blaVIM (93); blaOXA-23 (55); blaOXA-40 (30); ISAba1-blaOXA-51 (4) |
| Across KSA | [ | 2012 | Respiratory, blood, urine, abdomen, skin | Inpatients with DM | ICUs | 64 | blaVIM (92.2); blaOXA-23 (53.1); blaOXA-40 (29.7); blaSPM (28.1) |
| Across KSA | [ | 2012 | Respiratory, skin, wound, urine | Inpatients | Different hospital wards | 79 | OXA-51 (100); OXA-23 (97.5); OXA-72 (2.5); NDM-1 (1.2); OXA-23+NDM-1 (1.2) |
| Aseer | [ | 2013–2014 | Tracheal aspirate, sputum, wound and urine | Inpatients | Different hospital wards | 56 | blaOXA-23 (85.7); blaOXA-40 (5.4); blaOXA-58 (3.6); |
| Eastern region | [ | 2010–2012 | Respiratory, wound, urine | Inpatients and outpatients | Different hospital wards and adult ICU | 46 | blaOXA-23 (80.4); blaOXA-51 (2.2) |
| Eastern region | [ | 2008–2012 | Various clinical specimensb | Inpatients | Different hospital wards | 57 | blaOXA-23 (58); blaOXA-40 (13); blaVIM (94) |
| Eastern region | [ | 2014 | Rectal swab | Inpatients | ICUs | 35 | OXA-23 (100) |
| Eastern region | [ | 2014 | Sputum, blood, wound, nasal swab, pus swab | Inpatients and outpatients | Different hospital wards | 10 | blaOXA-23 (10); blaNDM-1 (30) |
| Eastern region | [ | NM | Sputum, throat, abdomen, catheter and endotracheal aspirates | Inpatients | ICUs | 5 | OXA-23 (100) |
| Madinah | [ | NM | Wound, sputum, urine, blood | Inpatients and outpatients | Different hospital wards | 48 | VIM-1 gene (37.9) |
| Makkah | [ | 2012–2014 | Blood, and skin wound | Inpatients | ICUs | 100a | OXA-51-like (94); OXA-23-like (91) |
| Riyadh | [ | 2011 | NM | Inpatients | Different hospital wards | 55 | blaOXA-23 (60.0); blaPER (49.1); blaGES (34.5); blaOXA-24 (3.6) |
| Riyadh | [ | 2006–2008 | Respiratory, wound and burn, blood, urine and other samples | Inpatients | Different hospital wards | 253 | OXA-23 (100); OXA-51 (100); OXA-58 (1.6) |
| Riyadh | [ | 2012 | Tracheal aspirate | Inpatients | Adults ICU | 12 | OXA-51 (100); OXA-23 (91.7); OXA-24/40 (8.3) |
| Riyadh | [ | 2006–2014 | Respiratory, wound and burn, blood, urine, and others samples | Inpatients | Different hospital wards | 503 | OXA-51-like (90.8); PER-1 (76.3) |
| Riyadh | [ | 2010 | Various clinical specimensb | Inpatients | Different hospital wards | 27 | OXA-23 (63); OXA-24/40 (3.7); ADC (96.3); GES-1 (18.5); GES-11 (11); GES-5 (3.7) |
| Riyadh-Khobar | [ | 2011–2013 | Blood, sputum, urine, respiratory, body fluid | Inpatients and outpatients | Different hospital wards | 80 | OXA-51 (100); OXA-23 (93) |
ICU intensive care unit, KSA Kingdom of Saudi Arabia, NM not mentioned
aIsolates were positive for extended spectrum beta lactamases
bTypes of clinical specimens were not specified in the study